Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CellCentric has out-licensed exclusively the development and commercialisation of an important programme focused on cancer to Takeda Pharmaceutical (Takeda).
Subscribe to our email newsletter
The deal is focused into the area of epigenetics, demonstrating the commercial interest in novel epigenetic targets beyond HDACs (histone deacetylases) and DNMTs (DNA methyltransferases ).
According to the deal, the therapeutic research is expected to be initiated by Takeda’s Research Group. Development of molecules stemming from this agreement will be completed by Millennium: The Takeda Oncology, which is responsible for Takeda’s global oncology development strategy.
As per the terms of the new agreement, CellCentric is expected to receive from an upfront payment and pre-clinical and clinical milestones, in addition to royalties from Takeda. Based on the royalties and milestones defined, the overall deal could be worth in excess of $200m to CellCentric over the course of the agreement.
Hiroyuki Odaka, general manager of the pharmaceutical research division at Takeda, said: “Epigenetics is an important area for novel oncology therapeutics. This new agreement demonstrates our commitment to researching and pioneering the best ways to treat cancer.”
Will West, CEO of CellCentric, said: “This licence is a strong endorsement of the way we are approaching innovation in epigenetics. This is an area that is no longer seen as just interesting, but as a necessity for pharmaceutical companies growing their armoury for tackling intractable diseases such as cancer.”